media1.jpg

PRESS / ARTICLES

Phosplatin Therapeutics receives US FDA Orphan drug designation for the use of PT-112 in patients with thymoma and thymic carcinoma

at THE ESMO 2018 Annual Meeting in munich, germany On October 22, the award for Best poster in the developmental therapeutics Category was given to the presentation of the phase i study of Pt-112 in advanced solid tumors, with Poster #437P, “PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors.” Click Here to Access The abstract

Phosplatin Therapeutics Presents Poster revealing PT-112’s immunogenic cell death (ICD) properties at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival

Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation

Phosplatin Therapeutics To present translational research in hematological malignancies at the ASH 2017 Annual Meeting. Click here to access the public abstract

Phosplatin Therapeutics announces Collaboration with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate Combination of PT-112 and Avelumab in Phase I / II Studies

Phosplatin Therapeutics presents data from its Phase I study of PT-112, selected for an oral discussion session at the ASCO 2017 Annual Meeting. Click here to access the public abstract

Phosplatin therapeutics to present along with the Institute of cancer research montpellier at the AACR 2017 Annual meeting

Phosplatin Therapeutics' research findings Presented at the 2016 AACR-NCI-EORTC International conference on Molecular Targets and cancer therapeutics

phosplatin therapeutics shares announcement on the launch of a combination clinical trial of PT-112 in Taiwan under Greater China collaboration agreement with sciclone pharmaceuticals

PHOSPLATIN THERAPEUTICS ANNOUNCES ITS COLLABORATION AND OPTION AGREEMENT FOR RIGHTS TO PT-112 IN GREATER CHINA

Phosplatin Therapeutics saddened by the death of the inventor of phosphaplatins, Rathindra N. Bose, PhD.

Phosplatin Therapeutics Announces the appointment of jose jimeno, MD, PhD as its chief medical officer

Phosplatin Therapeutics announces launch of Phase I clinical trial